Ensoma

Ensoma Pioneers Next-Generation In Vivo Approach to Deliver First “Off-the-Shelf” Genomic Medicines. The foundation of the next-generation approach is our meticulously designed Engenious™ vector, which enables us to directly apply gene modification technologies to stem cells or various cell types derived from these cells, such as T cells, B cells, and myeloid cells, without the need to collect potentially toxic stem cells from patients or pre-conditioning (e.g., chemotherapy). Our genomic medicines can be delivered through a simple, single injection.